Peter W. PENG, Author at MediaMedic

AASLD Voice of China | Peking University Hepatology Institute Shines with 10 Achievements at AASLD 2023

By Peter W. PENG 2023.11.14

From November 10th to 14th, the annual international event in hepatology—the American Association for the Study of Liver Diseases (AASLD) 2023—was grandly held in Boston, USA. According to incomplete statistics, more than 200 abstracts from Chinese experts and scholars were selected for oral presentations or poster exchanges at this conference, achieving fruitful results. Congratulations are extended here! The Beijing University People's Hospital and Peking University Hepatology Institute team achieved 1 oral and 9 poster presentations on scientific research in the fields of hepatic encephalopathy, fatty liver, hepatitis C, hepatitis B, and liver cancer. Some research abstracts are shared below, and "Hepatology Digest" takes you to appreciate the team's excellence.

AASLD2023 | Unveiling the Four Prestigious “Distinguished Awards” on the First Day of the Conference!

By Peter W. PENG 2023.11.14

From November 10th to 14th, the grand finale of the international hepatology scene, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023, unfolded in Boston, USA. AASLD, in its annual tradition, awarded the "Distinguished Awards" during the conference to honor peers who have made significant strides in the field of hepatology. The recipients of the coveted 2023 "Distinguished Awards" were announced on the conference's inaugural day (local time, November 10th).

Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

By Peter W. PENG 2023.11.14

On November 7, 2023, at 12:30 PM local time in Boston, the American Association for the Study of Liver Diseases (AASLD) held its sole pre-conference press briefing on Metabolic Associated Fatty Liver Disease (MASLD). Chaired by conference president Professor Norah Terrault, the event featured presentations by Professor Phuc Le of the Cleveland Clinic Lerner College of Medicine, who discussed his team's model predicting the changing prevalence of liver diseases in the U.S. until 2050. Dr. Zobair Younossi, the Global NASH Council Chairman, presented the latest findings on the correlation between food insecurity and MAFLD in American adolescents. Additionally, Dr. Rohit Loomba shared insights into the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD) and the challenges associated with it.

AASLD 2023: 17 Must-See Studies

By Peter W. PENG 2023.11.14

From November 10th to 14th, the annualHepatology Digest conference, the American Association for the Study of Liver Diseases (AASLD) 2023 held in Boston, USA. This event gathers the latest academic developments, clinical research findings, and major academic presentations in the field of liver disease. The following is a summary of 17 highly anticipated studies scheduled for presentation at the AASLD 2023 conference.

Dr. Liang Han: Phase III MATTERHORN Study Shows Significant Improvement in pCR for Neoadjuvant Treatment of Gastric Cancer with Pembrolizumab

By Peter W. PENG 2023.11.13

This 2023 ESMO Annual Meeting, in the field of gastric cancer, the global Phase III MATTERHORN study of the anti-PD-L1 antibody pembrolizumab in combination with the FLOT regimen for neoadjuvant treatment in resectable gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) was presented as a Late-breaking Abstract (LBA) with mid-term analysis results (Abstract No.: LBA73). The mid-term analysis showed a clinically and statistically significant improvement in the pathological complete response (pCR) rate, making MATTERHORN the first neoadjuvant Phase III immunotherapy regimen in gastric cancer to show positive results. "Tumor Outlook" invited Professor Liang Han from Tianjin Medical University Cancer Hospital to provide an in-depth interpretation of the study.

ESMO 2023 | Dr. Silvia Stacchiotti: Advancements and Challenges in Treating Metastatic Sarcoma

By Peter W. PENG 2023.11.13

Metastatic sarcoma presents a formidable challenge in the realm of cancer treatment. The sheer diversity of sarcoma subtypes and the necessity of tailoring treatments to each specific histology makes the quest for effective therapies all the more complex. In this article, we delve deeper into the current landscape of advancements and challenges in the treatment of metastatic sarcoma, guided by the insights of Professor Stacchiotti.

ESMO 2023 | Dr. Andrea Necchi: Advancements in Intravesical Delivery Systems for the Treatment of Bladder Cancer

By Peter W. PENG 2023.11.13

Bladder cancer presents a complex challenge that demands innovative approaches to treatment. In recent years, significant progress has been made in the development of intravesical delivery systems for targeted therapy in bladder cancer patients. This article aims to provide a comprehensive overview of the latest advancements in intravesical delivery systems, with a particular focus on the TAR200 and TAR21210 systems. The application of intravesical delivery systems holds profound clinical significance in the treatment of bladder cancer. These systems provide a continuous and controlled exposure of the tumor to therapeutic agents, significantly enhancing the likelihood of successful treatment outcomes. Moreover, intravesical delivery systems offer a valuable alternative to radical cystectomy, a surgical procedure that certain patients may decline or be medically unfit for. The ultimate goal is to preserve the bladder while achieving a cure and preventing disease progression

ESMO 2023 | Dr. Ryan J. Sullivan: When does targeted therapy outperform immunotherapy in patients with advanced melanoma?

By Peter W. PENG 2023.11.13

The landscape of advanced melanoma treatment has witnessed a remarkable transformation with the introduction of targeted therapies and immunotherapies. While immunotherapy has shown great promise in various cancer types, there exist specific scenarios where targeted therapy can outshine immunotherapy. In this article, we delve into the situations where targeted therapy may be the preferred choice for advanced melanoma patients, while also examining the comparative efficacy and potential side effects of these treatment approaches.

ESMO 2023 | Dr. Henrik Grönberg: Outcome Adaptive Design and Biomarker-Based Treatment Selection

By Peter W. PENG 2023.11.06

Prostate cancer remains a significant global health concern, predominantly affecting men. In recent groundbreaking research led by Dr. Henrik Grönberg, a novel approach known as outcome adaptive design was implemented to revolutionize the assessment of different drugs simultaneously. This innovative study design incorporated the dynamic adjustment of randomization probabilities based on individual patient outcomes, enabling the selection of the most suitable treatment for each person. Furthermore, the study harnessed the power of biomarkers, particularly circulating tumor DNA, to guide treatment selection, ultimately aiming to enhance patient outcomes and overall quality of life.

ESMO 2023 | Dr. Kjetil Boye: Emerging Therapeutic Strategies and Promising Drugs May Benefit Sarcoma Patients

By Peter W. PENG 2023.11.06

The field of sarcoma treatment is currently undergoing a remarkable transformation with the development of cutting-edge therapeutic strategies and promising drugs. This article aims to provide an in-depth overview of these emerging treatment options and highlight key findings from recent research, shedding light on the potential breakthroughs in sarcoma management.